BRINP2: A Potential Drug Target and Biomarker for Diseases (G57795)

Target Name: BRINP2

NCBI ID: G57795

BRINP2

BRINP2: A Potential Drug Target and Biomarker for Diseases

BRINP2 (DBCCR1L2) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation has led to a diverse expression profile, making it an attractive candidate for research into gene function and the development of new treatments.

BRINP2 is a non-coding RNA molecule that is located on chromosome 16 at position 276. It is a key regulator of the brain-derived RNA (BDRNA) network, which is a complex of non-coding RNAs that are produced in the brain and play a crucial role in the development and progression of various diseases. The BDRNA network is composed of several sub-networks, including the microRNA (miRNA) network, the long non-coding RNA (lncRNA) network, and theBRINP2-containing network.

BRINP2 is a member of the BRINP2 gene family, which is characterized by the presence of a unique exonic region that is composed of four repetitive nucleotides. This region is known as the Enhanced Transcription Factor (ETF) domain, which is responsible for driving the expression of BRINP2 RNA in the brain. The ETF domain is a key regulator of RNA stability and has been implicated in the development of various diseases, including cancer.

BRINP2 has been shown to play a role in the regulation of various cellular processes in the brain, including the development and progression of neurodegenerative diseases. For example, studies have shown that BRINP2 is involved in the regulation of neurotransmitter synthesis and release, as well as the modulation of ion channels in neuronal cells. It is also involved in the regulation of cellular processes that are critical for the development and progression of neurodegenerative diseases, such as the regulation of protein synthesis and the modulation of cellular signaling pathways.

BRINP2 is also a potential biomarker for various diseases, including cancer. The expression of BRINP2 has been shown to be altered in a variety of cancer types, and studies have shown that it is involved in the regulation of various cellular processes that are critical for cancer development and progression. For example, research has shown that BRINP2 is involved in the regulation of cell cycle progression, protein synthesis, and apoptosis, all of which are critical for cancer development and progression.

BRINP2 is also a potential drug target for various diseases, including cancer. The expression of BRINP2 has been shown to be altered in a variety of cancer types, and studies have shown that it is involved in the regulation of various cellular processes that are critical for cancer development and progression. For example, research has shown that BRINP2 is involved in the regulation of cell cycle progression, protein synthesis, and apoptosis, all of which are critical for cancer development and progression.

In conclusion, BRINP2 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation and involvement in the BDRNA network make it an attractive candidate for research into gene function and the development of new treatments. Further studies are needed to fully understand the role of BRINP2 in the development and progression of various diseases.

Protein Name: BMP/retinoic Acid Inducible Neural Specific 2

Functions: Inhibits neuronal cell proliferation by negative regulation of the cell cycle transition

The "BRINP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRINP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets